Daraxonrasib CAS 2765081-21-6

Deskripsyon pwodwi:

Non pwodwi: Daraxonrasib CAS 2765081-21-6

 

Sinonim:

RMC6236;

N-[21-ethyl-20-[2-(1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tChe micalbooketrazapentacyclo [17.5.2.12,5.19,13.022,26] octacosa-1 (25), 2,5 (28), 19,22 (26), 23-hexaen-7-yl] -2-methylcyclopropane-1-carboxamide;

trans-(1S,2S)-N-[(7S,13S)-21-etil-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3-piridinyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.1^2,5.1^9,13.0^22,26] octacosa-1 (25), 2,5 (28), 19,22 (26), 23-hexaen-7-yl] -2-methylcyclopropane-1-carboxamide;

 

Pwopriyete chimik ak fizik:

Aparans: poud blan rive blan -

Esè: Pi gran pase oswa egal a 99.0%

Dansite: 1.37±0.1 g/cm3

Solibilite: DMSO: Ti ka fonn: 1-10 mg / ml

Etanòl: ti ka fonn: 1-10 mg/ml

 

 

Itilizasyon:

RMC-6236 (Daraxonrasib) se yon inibitè oral, dirèk-sib, milti-selektif nan chemen RAS (ON), apwopriye pou rechèch kansè. Li anpeche siyal RAS pa bloke entèraksyon ki genyen ant RAS (ON) ak efektè en li yo. Li egzèse efè li lè li vize mitasyon RAS onkojenik (G12X, G13X, ak Q61X), ki se yon faktè komen nan kansè, ki gen ladan adenokarcinom ductal pankreyas (PDAC), kansè nan poumon ki pa ti selil (NSCLC), ak kansè kolorektal (CRC).

 

Si w enterese nan pwodwi nou yo oswa si w gen nenpòt kesyon, tanpri ou lib pou kontakte nou!

 

 

Pwodwi anba patant yo ofri pou rezon R & D sèlman. Sepandan, responsablite final la se sèlman nan achtè a.

Baj popilè: daraxonrasib cas 2765081-21-6, manifaktirè, founisè, faktori, achte, nan stock

• On: Temozolomid CAS 85622-93-1
• Pwochen: Baxdrostat CAS 1428652-17-8